Paper28964701
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M and 13 others. Lancet Gastroenterol Hepatol, 2017. Cited by 210 papers, by iCite.
Cite this record
ConductScience Library. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. Papers, record 28964701. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28964701
- Disease
- hepatitis B virus infection141 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
- PubMed
Connected records2
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics23
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antiviral Agents | Major topic |
| Hepatitis B | Major topic |
| Hepatitis D | Major topic |
| Interferon-alpha | Major topic |
| Nucleic Acids | Major topic |
| Polyethylene Glycols | Major topic |
| Polymers | Major topic |
| Adolescent | |
| Adult | |
| Alanine Transaminase | |
| Anemia | |
| Aspartate Aminotransferases | |
| Coinfection | |
| Drug Therapy, Combination | |
| Female | |
| Humans | |
| Liver | |
| Male | |
| Middle Aged | |
| Neutropenia | |
| Recombinant Proteins | |
| Thrombocytopenia | |
| Young Adult |
Source PubMed
Trials3
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT02233075 | REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT02876419 | A Long Term Follow-up Study of Patients From the REP 301 Protocol | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT05683548 | Replicor Compassionate Access Program | Background | ClinicalTrials.gov |
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Erratum in | 29254619 | Correction to Lancet Gastroenterol Hepatol 2017; 2: 877-89. | https://conductscience.org/library/papers/29254619 | PubMed |
| Comment in | 28964702 | Nucleic acid polymers: much-needed hope for hepatitis D? | https://conductscience.org/library/papers/28964702 | PubMed |
Cited by125
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 210 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42866838 | Tobevibart plus elebsiran in hepatitis D: crossing a therapeutic threshold. | Transl Gastroenterol Hepatol | 2026 | https://conductscience.org/library/papers/42866838 | PubMed |
| 41684842 | Unveiling DNAJB12 and DNAJB14 as crucial chaperones in hepatitis B and D virus particle morphogenesis. | iScience | 2026 | https://conductscience.org/library/papers/41684842 | PubMed |
| 41642349 | Insight into the Biology of Hepatitis B Virus and Recent Therapeutic Approaches. | Curr Microbiol | 2026 | https://conductscience.org/library/papers/41642349 | PubMed |
| 41214393 | Beyond viral suppression: assessing the immunotherapeutic potential of bepirovirsen for chronic hepatitis B. | Hepatol Int | 2026 | https://conductscience.org/library/papers/41214393 | PubMed |
| 41179730 | Hepatitis B functional cure: Current and future perspective. | World J Hepatol | 2025 | https://conductscience.org/library/papers/41179730 | PubMed |
| 41149045 | Chronic Hepatitis B: Current Management and Future Directions. | Diseases | 2025 | https://conductscience.org/library/papers/41149045 | PubMed |
| 41023586 | Genomic medicine in hepatology: mechanisms and liver treatment strategies. | Mol Med | 2025 | https://conductscience.org/library/papers/41023586 | PubMed |
| 41011799 | Hepatitis Delta Virus Infection: An Overview. | Pathogens | 2025 | https://conductscience.org/library/papers/41011799 | PubMed |
| 40872814 | Updates on Recent Advancements in Hepatitis D Virus Treatment. | Viruses | 2025 | https://conductscience.org/library/papers/40872814 | PubMed |
| 40790753 | Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D. | Virol J | 2025 | https://conductscience.org/library/papers/40790753 | PubMed |
| 40677987 | The Management of Chronic Hepatitis B: 2025 Guidelines Update from the Canadian Association for the Study of the Liver and Association of Medical Microbiology and Infectious Disease Canada. | Can Liver J | 2025 | https://conductscience.org/library/papers/40677987 | PubMed |
| 40624334 | Identification of low-molecular compounds that inhibit envelope formation of hepatitis B virus. | Sci Rep | 2025 | https://conductscience.org/library/papers/40624334 | PubMed |
| 40620504 | Nanoparticle-based therapeutic strategies for chronic liver diseases: Advances and insights. | Liver Res | 2025 | https://conductscience.org/library/papers/40620504 | PubMed |
| 40606936 | Hope on the horizon: Emerging therapies for hepatitis D. | World J Hepatol | 2025 | https://conductscience.org/library/papers/40606936 | PubMed |
| 40575639 | Advances in treatment of hepatitis delta virus infection: Update on novel investigational drugs. | World J Virol | 2025 | https://conductscience.org/library/papers/40575639 | PubMed |
| 40528594 | [Research progress on new drugs for the treatment of chronic hepatitis B virus infection]. | Zhonghua Gan Zang Bing Za Zhi | 2025 | https://conductscience.org/library/papers/40528594 | PubMed |
| 40087915 | Frequency, Severity and Impact of Pegylated Interferon Alpha-Associated Flares in Hepatitis D Infection. | J Viral Hepat | 2025 | https://conductscience.org/library/papers/40087915 | PubMed |
| 40008233 | Current and future therapeutic options for chronic hepatitis D virus infection. | Front Cell Infect Microbiol | 2024 | https://conductscience.org/library/papers/40008233 | PubMed |
| 39958926 | B cell dysfunction in chronic hepatitis B virus infection. | Liver Res | 2021 | https://conductscience.org/library/papers/39958926 | PubMed |
| 39858515 | Current Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases. | Biomolecules | 2025 | https://conductscience.org/library/papers/39858515 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| INTERFERON ALFA-2A | CHEMBL2108508 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL2108508 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28964701
GET https://conductscience.org/api/papers/v1/28964701/cited_by?page=2